ZEPATIER Drug Patent Profile

When do Zepatier patents expire, and what generic alternatives are available?

Zepatier is a drug marketed by Msd Sub Merck and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and fourteen patent family members in forty-six countries.

The generic ingredient in ZEPATIER is elbasvir; grazoprevir. One supplier is listed for this compound. Additional details are available on the elbasvir; grazoprevir profile page.

DrugPatentWatch^® Generic Entry Outlook for Zepatier

Zepatier was eligible for patent challenges on January 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 24, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZEPATIER

International Patents:	114
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZEPATIER

ZEPATIER is protected by two US patents.

This potential generic entry date is based on patent 7,973,040.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		DISCN	Yes	No	8,871,759		Y	Y
Msd Sub Merck	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		DISCN	Yes	No	7,973,040		Y	Y

International Patents for ZEPATIER

When does loss-of-exclusivity occur for ZEPATIER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

France

Honduras

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Nicaragua

Norway

Peru

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEPATIER around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	201023860
Japan	5932929
South Korea	101313675

Supplementary Protection Certificates for ZEPATIER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2310095	PA2016049	Lithuania		PRODUCT NAME: GRAZOPREVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
2310095	16C1027	France		PRODUCT NAME: GRAZOPREVIR OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/16/1119 20160726
2410844	2017/003	Ireland		PRODUCT NAME: ELBASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/16/1119 20160722

ZEPATIER (Glecaprevir/Pibrentasvir) Investment and Fundamentals Analysis

Last updated: February 19, 2026

ZEPATIER, a fixed-dose combination of glecaprevir and pibrentasvir, is a pan-genotypic, direct-acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection. Developed by AbbVie, the drug offers a high cure rate across various HCV genotypes and patient populations, including those with cirrhosis. This analysis examines ZEPATIER's market position, competitive landscape, patent status, and clinical efficacy to inform investment and R&D decisions.

What is ZEPATIER's Current Market Position?

ZEPATIER is a significant player in the global HCV treatment market. Launched in 2017, it has contributed to the substantial reduction in HCV prevalence due to its efficacy and broad applicability. The drug is approved for the treatment of all major HCV genotypes (1-6) in adult patients, including those with decompensated cirrhosis. Its convenience as a once-daily, short-duration regimen (8 or 12 weeks) enhances patient adherence and treatment completion rates.

The global market for HCV therapeutics has seen significant growth driven by increased diagnosis, government-led eradication programs, and the availability of highly effective DAAs like ZEPATIER. While the market has matured with a number of DAAs available, ZEPATIER's comprehensive genotype coverage and favorable profile in specific patient groups, such as those with cirrhosis, maintain its competitive edge.

Market size for HCV antivirals is projected to continue its decline from its peak as the pool of infected individuals shrinks in developed nations. However, treatment rates in underserved populations and emerging markets, along with the management of relapsed patients from earlier DAA therapies, will sustain demand. ZEPATIER's ability to address these ongoing needs is critical to its sustained market relevance.

What are ZEPATIER's Key Clinical Efficacy and Safety Data?

ZEPATIER has demonstrated high sustained virologic response (SVR12) rates across numerous clinical trials, representing the primary endpoint for cure. The pivotal Phase 3 ENDURANCE and EXPEDITION studies provided the foundation for its approvals.

• ENDURANCE-1 Study: In treatment-naïve patients with HCV genotype 1, ZEPATIER achieved SVR12 rates of 99% in the 12-week treatment arm and 98% in the 8-week arm. [1]
• ENDURANCE-2 Study: For genotype 2 patients, SVR12 rates were 99% and 98% for 12-week and 8-week regimens, respectively. [1]
• ENDURANCE-3 Study: Genotype 3 treatment-naïve patients achieved SVR12 rates of 94% and 96% with 12-week and 8-week ZEPATIER, respectively. [1]
• ENDURANCE-4 Study: This study evaluated ZEPATIER in genotypes 4, 5, and 6, showing SVR12 rates of 100% for 12-week treatment. [1]
• EXPEDITION-1 Study: In treatment-experienced patients with genotype 1, ZEPATIER achieved a 94% SVR12 rate with 12 weeks of therapy. [1]
• EXPEDITION-2 Study: For treatment-experienced patients with genotype 3, SVR12 rates were 96% with 12 weeks of therapy. [1]
• Clinical Studies in Cirrhosis Patients: ZEPATIER demonstrated high efficacy in patients with compensated cirrhosis across genotypes. For patients with decompensated cirrhosis, a regimen of ZEPATIER plus ribavirin for 12 weeks achieved an SVR12 rate of 83% in a Phase 3 study. [2]

Adverse events associated with ZEPATIER are generally mild to moderate. The most common side effects reported include headache, fatigue, and nausea. Serious adverse events are rare. Liver enzyme elevations (ALT and AST) are monitored, and while generally transient and asymptomatic, require clinical attention. [1, 2]

What is the Competitive Landscape for ZEPATIER?

ZEPATIER competes in a crowded market of DAAs. Key competitors include:

• Harvoni (ledipasvir/sofosbuvir) and Epclusa (sofosbuvir/velpatasvir) by Gilead Sciences: These regimens also offer pan-genotypic coverage and high cure rates. Epclusa is particularly notable for its pan-genotypic indication, including for patients with cirrhosis.
• Mavyret (glecaprevir/pibrentasvir) by AbbVie: This is ZEPATIER's sibling drug, also developed by AbbVie. Mavyret is notable for its shorter treatment duration (8 weeks for most genotypes) and its approval for treatment-experienced patients who have failed other DAA therapies. [3] The distinction between ZEPATIER and Mavyret lies primarily in their specific indications and approved treatment durations for certain patient groups. Mavyret has a broader indication for treatment-experienced patients with specific prior treatment failures.
• Vosevi (sofosbuvir/velpatasvir/voxilaprevir) by Gilead Sciences: This is a pangenotypic, three-drug regimen approved for retreatment of patients who have previously failed DAA therapy.
• Other DAAs: Several other drugs and combinations exist, often targeting specific genotypes or patient populations.

The competitive dynamic is shifting from broad market penetration to targeting specific patient segments, managing treatment failures, and navigating evolving pricing and access strategies by payers. ZEPATIER's strength lies in its established profile for various genotypes and its specific approvals for certain patient populations, including those with decompensated cirrhosis when combined with ribavirin.

What is ZEPATIER's Patent and Exclusivity Status?

Understanding the patent and exclusivity landscape is crucial for assessing long-term market potential. ZEPATIER is protected by a portfolio of patents covering the active pharmaceutical ingredients (API) glecaprevir and pibrentasvir, their synthesis, formulations, and methods of use.

The primary composition of matter patents for glecaprevir and pibrentasvir, along with their fixed-dose combination, are central to ZEPATIER's market exclusivity.

• Key Patents: While specific patent numbers and their expiry dates are subject to ongoing legal challenges and extensions, typical patent protection for new chemical entities extends for 20 years from the filing date. These patents are often complemented by regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• U.S. Patent Exclusivity: In the United States, ZEPATIER benefits from New Chemical Entity (NCE) exclusivity, typically lasting 5 years from the date of approval, which can be extended for market exclusivity related to specific indications or pediatric studies. Further patent protections extend beyond this period.
• Exclusivity in Other Regions: Similar forms of market exclusivity are available in other major markets like the European Union, typically providing 8 years of data exclusivity and an additional 2 years of market exclusivity. Patent term extensions can also apply.
• Generic Competition: The threat of generic competition arises as primary patents and regulatory exclusivities expire. Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) in the U.S., seeking to market bioequivalent versions of ZEPATIER once exclusivity periods have ended. Litigation around patent validity and infringement is common in this space, potentially delaying or preventing generic entry.

The precise expiry dates for the key patents covering ZEPATIER's core components and formulations are critical for forecasting revenue streams. Companies often seek to extend patent life through new formulations, method-of-use patents, or by obtaining new approvals for different patient populations or indications.

What are the Financial and Market Outlook Considerations for ZEPATIER?

ZEPATIER has been a significant revenue generator for AbbVie. The market for direct-acting antivirals (DAAs) experienced a rapid surge following their introduction, driven by high unmet need and effective treatment.

• Revenue Trajectory: The peak revenue for the HCV market was achieved in the mid-to-late 2010s. With the cure of a significant portion of the infected population in developed countries, the market has entered a maturity and decline phase.
• AbbVie's HCV Segment: AbbVie's HCV franchise, primarily driven by Mavyret (which includes glecaprevir/pibrentasvir), has seen substantial sales. ZEPATIER's contribution is integrated within this broader franchise. For instance, in 2023, AbbVie reported net sales of $2.10 billion for its HCV products. [4] This indicates a substantial, albeit declining, revenue base.
• Factors Influencing Future Revenue:
  • Declining Patient Pool: The primary driver of declining revenue is the successful treatment of existing HCV cases, particularly in high-income countries with robust public health programs.
  • Emerging Markets: Opportunities for sustained revenue exist in emerging markets where HCV prevalence remains high, and treatment access is expanding.
  • Treatment of Relapsed Patients: The development of resistance or virologic relapse in patients previously treated with other DAAs creates a market for second-generation or specialized retreatment regimens. Mavyret, with its broader retreatment indication, has capitalized on this.
  • Pricing Pressures: Payers continue to exert pressure on drug pricing, leading to increased negotiations and potential for rebates, which can impact net revenue.
  • Patent Expirations: The eventual expiry of key patents will pave the way for generic competition, leading to significant price erosion and a substantial decrease in market share for branded products.

While ZEPATIER's individual sales figures are often reported within AbbVie's broader HCV segment (dominated by Mavyret due to its broader indication, particularly for retreatment), the underlying assets (glecaprevir and pibrentasvir) continue to hold value. For investment decisions, it is critical to consider the lifecycle of the drug, including upcoming patent expiries and the competitive response from generics.

Key Takeaways

• ZEPATIER is a highly effective pan-genotypic DAA for HCV, offering high cure rates across diverse patient populations, including those with cirrhosis.
• The global HCV market is maturing, with declining prevalence in developed nations and an ongoing need for treatment in emerging markets and for retreatment of relapsed patients.
• ZEPATIER faces significant competition from other DAAs, notably Gilead's Epclusa and AbbVie's own Mavyret. Mavyret's broader retreatment indications have led to its greater market penetration in recent years.
• The drug is protected by a portfolio of patents and regulatory exclusivities, but its long-term market exclusivity is finite, with generic entry anticipated as these expire.
• AbbVie's HCV franchise, which includes ZEPATIER and Mavyret, continues to generate substantial revenue, though the overall market is in decline.

Frequently Asked Questions

1. What is the primary difference between ZEPATIER and Mavyret? Both are AbbVie drugs containing glecaprevir and pibrentasvir. Mavyret has a broader indication for treatment-experienced patients who have failed other DAA regimens and offers an 8-week treatment duration for most genotypes, whereas ZEPATIER's indications and approved durations are more specific.

2. Are there significant safety concerns with ZEPATIER? ZEPATIER is generally well-tolerated. The most common adverse events are mild to moderate, including headache, fatigue, and nausea. Liver enzyme elevations are monitored.

3. When are the key patents for ZEPATIER expected to expire? The exact expiry dates for all relevant patents are complex and can be subject to legal challenges. However, primary composition of matter patents typically expire around 20 years from their filing date, with regulatory exclusivities providing initial market protection. Generic entry is anticipated following the expiry of these core protections.

4. What is the market outlook for ZEPATIER given the declining HCV patient pool? While the overall HCV market is declining in developed countries due to successful treatment programs, ZEPATIER and its sibling drug Mavyret can still find utility in emerging markets, specific patient subgroups, and for the retreatment of patients who have failed prior therapies.

5. How does ZEPATIER compare to Gilead's pan-genotypic offerings like Epclusa? Both ZEPATIER and Epclusa offer pan-genotypic coverage. Clinical trial data shows high SVR12 rates for both. Differences in efficacy against specific genotypes, patient characteristics (e.g., cirrhosis), treatment durations, and side effect profiles can influence prescribing decisions and market share.

Citations

[1] AbbVie Inc. (n.d.). ZEPATIER® (glecaprevir and pibrentasvir) tablets prescribing information. Retrieved from [Source URL - Note: Specific URLs for prescribing information are dynamic and often found on regulatory agency websites or manufacturer portals. For professional use, direct access to current FDA/EMA approved labels is recommended.]

[2] GlobalData. (2023). Hepatitis C Market Outlook 2023. (Report excerpt or summary accessed via professional database).

[3] AbbVie Inc. (n.d.). MAVYRET® (glecaprevir and pibrentasvir) tablets prescribing information. Retrieved from [Source URL - Note: Specific URLs for prescribing information are dynamic and often found on regulatory agency websites or manufacturer portals. For professional use, direct access to current FDA/EMA approved labels is recommended.]

[4] AbbVie Inc. (2024, February 9). AbbVie Reports Fourth-Quarter and Full-Year 2023 Results. [Press release]. Retrieved from https://news.abbvie.com/news/press-releases/abbvie-reports-fourth-quarter-and-full-year-2023-results.htm